Search Results

Newron Pharmaceuticals S.p.A., a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, welcomed investors, analysts and media to its well-attended investor day in New York City.

Newron Pharmaceuticals S.p.A. today announced that it will host its 2024 Investor Day on Tuesday, June 25, 2024, at Convene, 530 Fifth Avenue (between 44th and 45th Streets) in New York City, from 9:00-11:00 AM EDT.

Newron Pharmaceuticals S.p.A., a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, announced that it will host its 2024 Investor Day on Tuesday, June 25, 2024, in New York City.

Newron Pharmaceuticals S.p.A. presented four posters and two oral presentations at the 2024 Annual Congress of the Schizophrenia International Research Society from 3-7 April in Florence, Italy.

Newron Pharmaceuticals S.p.A. announced its financial results and operational highlights for the business year ended December 31, 2023, and provided an outlook for 2024.

Newron Pharmaceuticals S.p.A. presents additional results from the international, randomized, double-blind, placebo-controlled study 008A that evaluated the efficacy and safety of evenamide as add-on treatment in 291 patients not benefitting from their second-generation antipsychotic medication, including clozapine.

Newron Pharmaceuticals S.p.A. reports agreement with the European Investment Bank on an amendment to certain terms of its 2018 financing agreement.

Newron Pharmaceuticals S.p.A. announced positive top-line results from its potentially pivotal study 008A, evaluating the safety, tolerability and efficacy of evenamide in patients with chronic schizophrenia currently being treated with a second-generation antipsychotic including clozapine, but demonstrating an inadequate response to that treatment.